Evidence map›Paper›PMID 24707145›Full record

Trial reportWorld journal of gastroenterology2014

Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: report of an efficacy study.

Charles Asabamaka Onyekwere, Joan Nwabuaku Odiagah, Rufina Igetei, Amancia Olufunmilayo Duro Emanuel, Francis Ekere, Stella Smith

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Infections withWorld journal of gastroenterology · 2019
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Charles Asabamaka OnyekwereCharles Asabamaka Onyekwere, Joan Nwabuaku Odiagah, Rufina Igetei, Amancia Olufunmilayo Duro Emanuel, Francis Ekere, Gastroenterology unit, Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos 999062, Nigeria.
Joan Nwabuaku OdiagahCharles Asabamaka Onyekwere, Joan Nwabuaku Odiagah, Rufina Igetei, Amancia Olufunmilayo Duro Emanuel, Francis Ekere, Gastroenterology unit, Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos 999062, Nigeria.
Rufina IgeteiCharles Asabamaka Onyekwere, Joan Nwabuaku Odiagah, Rufina Igetei, Amancia Olufunmilayo Duro Emanuel, Francis Ekere, Gastroenterology unit, Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos 999062, Nigeria.
Amancia Olufunmilayo Duro EmanuelCharles Asabamaka Onyekwere, Joan Nwabuaku Odiagah, Rufina Igetei, Amancia Olufunmilayo Duro Emanuel, Francis Ekere, Gastroenterology unit, Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos 999062, Nigeria.
Francis EkereCharles Asabamaka Onyekwere, Joan Nwabuaku Odiagah, Rufina Igetei, Amancia Olufunmilayo Duro Emanuel, Francis Ekere, Gastroenterology unit, Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos 999062, Nigeria.
Stella SmithCharles Asabamaka Onyekwere, Joan Nwabuaku Odiagah, Rufina Igetei, Amancia Olufunmilayo Duro Emanuel, Francis Ekere, Gastroenterology unit, Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos 999062, Nigeria.
Lagos State University Teaching Hospital · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the efficacy of a standard triple therapy (comprising rabeprazole, clarithromycin, and amoxicillin) for Helicobacter pylori (H. pylori) eradication, noting factors that influence the outcome and documenting any adverse events.

methodsFollowing institutional ethical approval, fifty consecutive and consenting symptomatic patients with evidence of H. pylori infection by either a positive urea breath test (UBT) and/or a campylobacter-like organism test who presented to the Gastroenterology clinic of Lagos State University Teaching Hospital between 2012 and 2013 were recruited into the study. Patients were openly randomized to either a 7-d or a 10-d regimen of amoxicillin 1 g, clarithromycin 500 mg and rabeprazole 20 mg twice daily. The extent of symptom resolution was noted following the treatment, and at the end of one month after the completion of treatment, a repeat UBT was performed in each patient to document the eradication of the infection. All data (demographics, symptoms, and eradication rates) were collated and analyzed with SPSS version 18.

resultsForty-seven patients completed the study (three were excluded from the analysis for breaching the study protocol). The patients included 18 males and 29 females within the age range of 13-80 years (mean 43.7, SD 16.8). The clinical features of the study subjects were dyspepsia, reflux symptoms and features of gastrointestinal bleeding. The average eradication rate was 87.2%. Eighteen subjects were enrolled in the 7-d arm, while 29 were in the 10-d arm. There was no statistically significant difference in the age or sex distributions of the two arms. There was no significant advantage of the 10-d treatment duration over the 7-d duration (P = 0.78), and the eradication outcomes were not influenced by the gender or age of the subjects. No adverse effects were reported in either arm.

conclusionThe triple therapy regime, employing a combination of amoxicillin, clarithromycin and rabeprazole, showed great efficacy and safety in the eradication of H. pylori, and this outcome was not influenced by gender or age. No difference was observed between the 7-d and 10-d regimens.

Indexed as

Helicobacter pyloriAdolescentAdultAgedAged, 80 and overAmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsBreath TestsClarithromycinFemaleHelicobacter InfectionsHumansMaleMiddle AgedRabeprazoleAmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsClarithromycinRabeprazoleUreaAmoxicillin clarithromycinEradication therapyHelicobacter pyloriRabeprazole triple therapy

Identifiers

PMID24707145
PMCPMC3974529
OpenAlexW1996813172

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.